CRISPR Therapeutics Faces Challenges and Opportunities Ahead
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2026
0mins
Should l Buy CRSP?
Source: NASDAQ.COM
- Poor Revenue Performance: CRISPR Therapeutics' first approved product, Casgevy, generated only $3.5 million in revenue in 2025, a significant drop from $37.3 million in 2024, indicating limited market acceptance despite its approval, which adversely affects the company's overall financial health.
- Slow Clinical Progress: The company has struggled with clinical advancements in recent years, and while promising candidates like CTX310 and SRSD107 show potential, the lack of sufficient clinical results has undermined investor confidence, leading to a continued decline in stock price.
- Revenue Dependency on Partnerships: Casgevy's sales revenue heavily relies on collaboration with Vertex Pharmaceuticals, with CRISPR sharing 40% of the profits, which constrains its profitability and exacerbates financial pressures on the company.
- Future Potential to Explore: Despite numerous challenges, Casgevy generated $116 million in revenue in 2024, and several of CRISPR's candidates, such as CTX310, could achieve breakthroughs in the coming years, potentially providing substantial market opportunities if successfully launched.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 45.750
Low
50.00
Averages
78.89
High
105.00
Current: 45.750
Low
50.00
Averages
78.89
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cathie Wood Shifts AI Investment Focus to Healthcare
- Portfolio Rebalancing: Cathie Wood's aggressive shift from mega-cap tech and semiconductor stocks to increasing her stake in Tempus AI reflects her strong conviction in AI innovation within healthcare, particularly in disease detection and drug development.
- Market Trend Insight: As AI infrastructure becomes crowded and capital-intensive, ARK Invest's strategic pivot towards application-driven intelligence indicates that healthcare is poised to be the next significant frontier for AI value creation, especially in the transformation of precision medicine.
- Clinical Data Utilization: Tempus AI leverages vast clinical and genomic datasets to drive AI-powered diagnostics and treatment recommendations, and despite its shares declining over 20% year-to-date, ARK's continued buying demonstrates unwavering confidence in its long-term potential.
- Industry Structural Shift: The pharmaceutical sector is expected to face a patent cliff in the next five years, creating opportunities for AI-native platforms to accelerate drug discovery and optimize clinical trials, with emerging players like Totaligent enhancing their biologics-driven data capabilities through strategic acquisitions.
See More
Cathie Wood's ARK Divests Meta Shares to Invest in This AI Stock.
- ARK Invest's Stock Move: Cathie Wood's ARK Invest sold its shares in Meta on a significant day for the company.
- New Investment Focus: The firm redirected its investment towards Tempus AI, a healthcare technology company specializing in artificial intelligence.
See More
Cathie Wood's ARK Divests Meta Shares to Invest in This AI Stock.
- ARK Invest's Stock Move: Cathie Wood's ARK Invest sold its shares in Meta on a significant day for the company.
- New Investment Focus: The firm redirected its investment towards Tempus AI, a healthcare technology company specializing in artificial intelligence.
See More
CRISPR THERAPEUTICS AG: LEERINK PARTNERS REDUCES TARGET PRICE FROM $74 TO $60
- Company Announcement: CRISPR Therapeutics has announced a reduction in its target price from $74 to $60.
- Market Impact: This price cut may influence investor sentiment and market performance for the company.
See More
AvaíBio Initiates α-Klotho Cell Bank Creation
- Key Milestone: AvaíBio, in collaboration with Austrianova, has initiated the creation of a Master Cell Bank (MCB) that overexpresses the α-Klotho protein, a process that clones a single genetically engineered cell into tens of millions of identical copies, establishing a foundation for future cell therapies and ensuring product consistency and scalability.
- Market Potential: The decline of α-Klotho protein is linked to various age-related diseases, with projections indicating that the Alzheimer's market alone could reach $32.8 billion by 2033, highlighting the significant demand for anti-aging treatments.
- Technological Advantage: The cell bank will utilize Austrianova's Cell-in-a-Box® technology, which allows therapeutic cells to continuously secrete proteins without triggering immune rejection, thereby enhancing the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program using the same encapsulation technology, demonstrating the company's broad application potential in regenerative medicine and attracting institutional capital at unprecedented speed.
See More
AvaíBio Initiates Master Cell Bank for α-Klotho Production
- Critical Milestone: AvaíBio, in collaboration with Austrianova, has successfully initiated the creation of a Master Cell Bank (MCB) for α-Klotho protein, marking a significant advancement in the company's efforts to develop anti-aging therapies and laying a solid foundation for future cell therapy products.
- Massive Market Potential: With the Alzheimer's market projected to reach $32.8 billion by 2033, AvaíBio's technology is poised to play a crucial role in addressing this major health challenge, enhancing the company's market position in the biopharmaceutical sector.
- Technological Advantage: The Master Cell Bank will utilize Austrianova's Cell-in-a-Box® technology, ensuring that cells are protected within a biocompatible shell for continuous protein secretion without triggering immune rejection, thereby improving the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, leveraging the same encapsulation technology, showcasing the company's broad application potential in regenerative medicine and attracting significant institutional capital interest.
See More
Cathie Wood Shifts AI Investment Focus to Healthcare
- Portfolio Rebalancing: Cathie Wood's aggressive shift from mega-cap tech and semiconductor stocks to increasing her stake in Tempus AI reflects her strong conviction in AI innovation within healthcare, particularly in disease detection and drug development.
- Market Trend Insight: As AI infrastructure becomes crowded and capital-intensive, ARK Invest's strategic pivot towards application-driven intelligence indicates that healthcare is poised to be the next significant frontier for AI value creation, especially in the transformation of precision medicine.
- Clinical Data Utilization: Tempus AI leverages vast clinical and genomic datasets to drive AI-powered diagnostics and treatment recommendations, and despite its shares declining over 20% year-to-date, ARK's continued buying demonstrates unwavering confidence in its long-term potential.
- Industry Structural Shift: The pharmaceutical sector is expected to face a patent cliff in the next five years, creating opportunities for AI-native platforms to accelerate drug discovery and optimize clinical trials, with emerging players like Totaligent enhancing their biologics-driven data capabilities through strategic acquisitions.
See More
Cathie Wood's ARK Divests Meta Shares to Invest in This AI Stock.
- ARK Invest's Stock Move: Cathie Wood's ARK Invest sold its shares in Meta on a significant day for the company.
- New Investment Focus: The firm redirected its investment towards Tempus AI, a healthcare technology company specializing in artificial intelligence.
See More
Cathie Wood's ARK Divests Meta Shares to Invest in This AI Stock.
- ARK Invest's Stock Move: Cathie Wood's ARK Invest sold its shares in Meta on a significant day for the company.
- New Investment Focus: The firm redirected its investment towards Tempus AI, a healthcare technology company specializing in artificial intelligence.
See More
CRISPR THERAPEUTICS AG: LEERINK PARTNERS REDUCES TARGET PRICE FROM $74 TO $60
- Company Announcement: CRISPR Therapeutics has announced a reduction in its target price from $74 to $60.
- Market Impact: This price cut may influence investor sentiment and market performance for the company.
See More
AvaíBio Initiates α-Klotho Cell Bank Creation
- Key Milestone: AvaíBio, in collaboration with Austrianova, has initiated the creation of a Master Cell Bank (MCB) that overexpresses the α-Klotho protein, a process that clones a single genetically engineered cell into tens of millions of identical copies, establishing a foundation for future cell therapies and ensuring product consistency and scalability.
- Market Potential: The decline of α-Klotho protein is linked to various age-related diseases, with projections indicating that the Alzheimer's market alone could reach $32.8 billion by 2033, highlighting the significant demand for anti-aging treatments.
- Technological Advantage: The cell bank will utilize Austrianova's Cell-in-a-Box® technology, which allows therapeutic cells to continuously secrete proteins without triggering immune rejection, thereby enhancing the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program using the same encapsulation technology, demonstrating the company's broad application potential in regenerative medicine and attracting institutional capital at unprecedented speed.
See More
AvaíBio Initiates Master Cell Bank for α-Klotho Production
- Critical Milestone: AvaíBio, in collaboration with Austrianova, has successfully initiated the creation of a Master Cell Bank (MCB) for α-Klotho protein, marking a significant advancement in the company's efforts to develop anti-aging therapies and laying a solid foundation for future cell therapy products.
- Massive Market Potential: With the Alzheimer's market projected to reach $32.8 billion by 2033, AvaíBio's technology is poised to play a crucial role in addressing this major health challenge, enhancing the company's market position in the biopharmaceutical sector.
- Technological Advantage: The Master Cell Bank will utilize Austrianova's Cell-in-a-Box® technology, ensuring that cells are protected within a biocompatible shell for continuous protein secretion without triggering immune rejection, thereby improving the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, leveraging the same encapsulation technology, showcasing the company's broad application potential in regenerative medicine and attracting significant institutional capital interest.
See More
